3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
3
Colorectal Neoplasms
2
Thyroid Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
11
trametinib
8
selpercatinib
7
pembrolizumab
7
dabrafenib
7
Nivolumab
7
Iodine-131
6
lenvatinib
5
Specimen Handling
5
Biopsy
5
cabozantinib
4
Vemurafenib
4
Iodine-124
4
larotrectinib
3
durvalumab
3
binimetinib
3
anlotinib
3
Ipilimumab
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Cyclophosphamide
3
Cetuximab
3
vandetanib
2
ulixertinib
2
pralsetinib
2
omipalisib
2
defactinib
2
copanlisib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
naporafenib
×
1 year
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled